I will start with plasma sodium concentration because it is usually first on the request forms, not because it is the most important or useful measurement.
How one thinks about plasma sodium concentration depends to some extent on how one thinks about body water compartments. A simple picture of the body water is that it is either extracellular or intracellular. I suggest that there are homeostatic systems which separately control the volume of the extracellular fluid (ECY) and the volume of the intracellular fluid (ICV). The control of ECY is a well-aired topic, and although the mechanisms, and indeed the controlled variable, are not agreed, it is clear that the basis of the control system is that the ECY is kept constant by mechanisms which keep ·Based on a plenary lecture Iliven at the National Meeting of the Association of Clinical Biochemists al BirminBham on 13 July 1980. the body sodium constant (with secondary changes in water to keep the sodium concentration constant). Reduction or expansion of the ECY (as in 'dehydration' or oedema) will therefore not. of themselves lead to change in the concentration of sodium in plasma. This is well appreciated for oedema, but there is still a reluctance to accept that it is also true for 'dehydration' (due to saline depletion). That might be because 'dehydration' can be a difficult clinical problem, in which case the mistaken feeling might be that any information is better than none. We cannot readily offer a measure of ECY (or total body sodium), which is what is required, and we should clearly say so. The most we can do is to offer measures of blood components such as plasma proteins, which increase in concentration when the ECV shrinks (Who does plasma albumin as an urgent or out-of-hours measurement 1) or which indicate consequences of the fall in extracellular fluid (such as an increase in plasma urea).
The concept that intracellular volume is controlled is a relatively new one (for further discussion see Morgan and Thomas'), The essential function of the system is probably to prevent changes in brain cell volume, as the obvious effects of changes in cell volume are changes in brain cell function with confusion, delirium, convulsions, and coma.s The system is usually regarded as working through osmolality control involving the osmoreceptors and the thirst centre leading to changes in the rate of secretion of anti-diuretic hormone and water intake. However the system responds to changes in plasma osmolality only if they are associated with changes in cell water and cell volume.
ICY is determined by the particle or osmole concentration in the cell (Osm)ic and the total number of particles or osmoles within the cell; Osm IO ! ' The plasma osmolality is always the same as the intracellular osmolality so that
If the total number of osmoles is constant then the cell volume and plasma osmolality (and therefore plasma sodium concentration) will be inversely related. That is why what is a cell volume control 275 system has been regarded as an osmolality control system.
It has, however, been clear since the early experiments of Verney8 that the system is not strictly an osmolality control system. He noted that a rise in plasma urea raised the plasma osmolality but did not increase the secretion of anti-diuretic hormone. Urea would diffuse into the cells and increase both the intracellular and extracellular osmolality but would have little, if any, effect on intracellular volume.
Arieff and his colleagues-pointed out that whereas most patients with acute water overload and hyponatraemia have neurological symptoms and that half of them die many patients with chronic water overload and hyponatraemia do not have symptoms and are not in danger. This lack of symptoms suggests that brain cell volume is not increased in patients with chronic water overload in spite of a low plasma sodium and osmolality. Equation 1 makes it clear that this could happen if there was a decrease in the total number of osmoles in the cell. There is experimental evidence for such a reduction in chronic water overload, at least in brain cells (reviewed by Bradbury'), It is clear that a low plasma sodium concentration <and/or plasma osmolality) is not necessarily bad for the patient (although it may itself be the consequence of a serious disorder). Indeed, to treat a 'low plasma sodium' in a patient without neurological symptoms can be disastrous as it can produce symptoms presumably by making abnormal a brain cell volume which had become normal through the compensatory reduction in cell osmoles. We should be measuring intracellular volume and not plasma osmolality, but we cannot, and our only index of it is the presence or absence of neurological symptoms.
My impression of what has been happening is that plasma sodium is being measured in many or most hospital patients (at least the medical and surgical ones) and that the occasional patient is found to have gross hyponatraemia (and a low plasma osmolality) which is then investigated and sometimes treated. It seems to me that a better approach would be to limit the measurement of plasma sodium concentration to patients with neurological symptoms which might be due to changes in brain cell volume. Plasma osmolality would be measured if the plasma sodium was abnormal. The particular neurological picture can be bizarre. We have recently seen a man with all the symptoms of a brain stem haemorrhage 'get up and walk' when his acute hyponatraemia was corrected.
The other indications for the measurement of plasma sodium are more difficult to define. The plasma sodium concentration does not really detect Morgan loss of extracellular fluid: 'dehydration'. The measurement has some usefulness in the diagnosis of primary aldosteronism, but that is a rare disorder. The regular routine measurement of plasma sodium concentration in patients having intravenous solutions after a surgical operation probably makes up a considerable proportion of our total workload. Unfortunately, a fall in the plasma sodium concentration is sometimes interpreted as a lack of sodium, whereas it is usually due to water overload from the continued administration of water (dextrose solution) in the face of the inevitable stress-driven secretion of anti-diuretic hormone."
These arguments suggest that most measurements of plasma sodium concentration are unnecessary and that abnormal values are often misinterpreted. On the other hand, it could be argued that there is a need for more thorough investigation of patients with neurological symptoms, It is well known that 'space-occupying lesions' of the plasma, such as hyperlipidaemia, can cause a fall in plasma sodium concentration without a fall in the concentration of sodium in plasma water or a fall in plasma osmolality. It is therefore remarkable that there has been so much concern with the measurement of plasma sodium concentration and so little concern with the measurement of plasma osmolality or of sodium activity in plasma water as with ion specific electrodes. Indeed, the latter is regarded as something of a nuisance as it gives values different from that in plasma. (This is an important matter because it is electrode-based systems that will be used increasingly on intensive care wards.)
Potassium
The case for the 'routine' and widespread measurement of plasma potassium concentration is at first sight much stronger than that for the measurement of plasma sodium concentration. It might be argued that the main reason we measure sodium on so many samples is that we measure sodium and potassium on the same machine. In other words, if we need to measure plasma potassium we might as well measure plasma sodium.
Extreme changes in the plasma potassium concentrations are undoubtedly dangerous. (The argument about whether or not there are associate changes in the cell potassium is probably not relevant to this risk.) Dangerous hyperkalaemia is probably restricted to ill patients with both. poor renal function and an increased load of potassium for excretion. Unsuspected hyperkalaemia, detected as a result of screening relatively well patients, must be unusual and, in most cases, is probably the result of haemolysis. Table 1 Analytical (SD AN) and within-person (SD wp) standard deviation of plasma potassium (mmolll) in healthy persons and treated patients with heart failure; and the differences in plasma potassium that can reasonably be interpreted as a biological change in the valuefor plasma potassium and as a change in the patient's setting to differ by more than 1·1 mmol/l before one could conclude with certainty that the patient's setting had changed. It is difficult to see how patients can be monitored, and have their antihypokalaemia treatment sensibly adjusted, on the basis of single determinations in the face of such a large within-person variation.
CLINICAL INDICA TlONS
What are the situations in which the measurement of plasma potassium is regarded as essential? The most common is routine measurement before operations, as anaesthetists prefer to see a normal plasma potassium (however it is produced) before they give a general anaesthetic," Again, the argument is sound for gross abnormalities of the plasma potassium (which are unlikely in symptomless patients), but the case for making measurements on symptomless patients is much less well founded. Nor do we know what deviation from the reference range increases the operative risk to the patient. A recent review implied that if these measurements were available before operation, well and good, but they were not an absolute requirement.P It certainly seems to be the case that attitudes to this problem vary greatly between anaesthetists and between surgical specialties.
The measurement of plasma potassium is clearly essential in patients with arrhythmia or muscle weakness or polyuria, or in a patient with hypertension who might have primary aldosteronism. It may be justified before a patient is started on digoxin. There is a strongly held view that monitoring of the plasma potassium is necessary in patients after open-heart surgery, who are loaded with potassium in order to maintain a high plasma potassium which is believed to decrease the risk of arrhythmia. The plasma potassium is also commonly monitored in patients being given intravenous saline or dextrose solutions after surgical operation. In both situations the potassium concentration is used by some to adjust the amount of potassium given with a fineness which it is difficult to justify in
Healthy persons o·1
Heart failure patients O· 1
Gross hypokalaemia can cause cardiac arrhythmia, renal damage to the proximal or distal tubules and muscle weakness or even paralysis. However, the plasma potassium in patients with these effects is usually very low (say less than 2·5 mmol/I), much lower than the lower limit of the reference range (say 3· 5 mmol/l), The question is whether the patients with the more common degrees of hypokalaemia (plasma potassium between 3' 5 and 2·5 mmolJl), who are usually symptom free, are nevertheless at increased risk of cardiac arrhythmia or of subclinical renal damage. There is a growing view that there is a risk of arrhythmia only if the plasma potassium is less than 3·0 mmol/I (particularly in patients not taking digoxin). We have looked for proximal tubular damage in unselected patients with hypokalaemia using as indices the urinary excretion of~2-microglobulin and Nacetyl-B-glucosaminidase. The results so far available suggest that the frequency of tubular damage is very low unless the plasma potassium is below 3·0 mmol/l or thereabouts (Tete-Donker et al., in preparation).
It is increasingly likely that there is a zone of low plasma potassium where there is a difference from the reference range but there is no disadvantage to the patient. 6 This distinction between difference and disadvantage is an important one because it determines which and how many patients need to be given something to raise their plasma potassium. Among unselected patients investigated in a busy general hospital, or in outpatients given diuretics, the number with a plasma potassium less than 3·0 rnrnol/l is only 15% of those with a plasma potassium less than 3·5mmol/l. Values less than 3·0mmol/l are surprisingly unusual in patients taking diuretics (about 5%), and the case for giving potassium supplements routinely to patients on diuretics is now hotly disputed. It is important to bear in mind that both potassium supplements and potassiumsparing diuretics can cause hyperkalaemia, and Lawson et al:" suggested that the disadvantages of these treatments may outweigh their largely theoretical advantages. It is particularly worrying to recall that most potassium supplements and potassium-sparing diuretics are probably given in general practice with little or no monitoring of the plasma potassium concentration.
I have discussed the plasma potassium as if a single estimate is a reliable estimate of the average value about which the patient's values fluctuate, that is, the patient's setting." Although the analytical imprecision for plasma potassium concentration is small, the total within-person variability is not (Table 1 ). In patients with heart failure on a fixed treatment, the value on two occasions would have Zone Table 2 Relative frequency (%) of values in the three zones ofcombination ofplasma urea and plasma creatinine (Figure) in several groups ofpatients Plasma creatinine (}Jmol / I ) was heart failure or saline depletion'! whereas other studies have suggested that excessive treatment with diuretics is the commonest cause.IS The excessively raised urea in patients with heart failure is probably due largely to increased urea production from tissue breakdown.v' In heart failure, the higher the plasma urea, the poorer the prognosis, so that in this situation, as in patients thought to have had an internal haemorrhage, the plasma urea is a useful measurement even if the rise in it is not due to a fall inGFR.
Relation between plasma urea and plasma creatinine in hospital patients. Zone B, the renal zone, defines the limits of the relation observed in patients with acute renal failureP When the plasma urea is less than 10 mmolll, or the plasma creatinine is less than 200 umolll, then the values have not been allocated to a zone.
There is no doubt that in the acutely ill patients who might be saline-depleted, the plasma urea is regarded as a useful measurement even in the absence of a plasma creatinine (which few laboratories provide out of hours). The difficulties are that, without a plasma creatinine, acute renal failure cannot be excluded as the cause of the raised urea, and even if the patient is saline-depleted it takes time for urea to accumulate in the body so that a normal 278 the light of the spontaneous variation in the plasma potassium concentration.
Chloride and bicarbonate I will not comment in any detail on the need to measure chloride and bicarbonate in plasma. Some laboratories have taken both of these out of their routine set of plasma electrolytes, and we have just stopped bicarbonate measurements on our Vickers M300 analyser because of their high cost. It seems to be accepted that the case for screening for abnormal plasma bicarbonate is not as good as the apparent case for screening for abnormal plasma sodium and potassium.
Urea and creatinine
Few would doubt the need to screen for abnormal plasma urea or plasma creatinine or both, although the evidence to justify this on economic or clinical grounds is lacking.
Plasma urea was introduced as a simple way of screening for renal failure, that is, a low glomerular filtration rate (GFR). It was recognised, however, that a rise in plasma urea, unlike a rise in plasma creatinine, could be due not only to a fall in GFR but also to either a rise in the tubular reabsorption of urea (as in dehydration due to saline depletion) or an increase in the load of urea to be excreted. Nevertheless reasons other than a fall in GFR are regarded as unusual, so that plasma urea and plasma creatinine are still regarded as more similar than different.
In our experience, however, there is little relation between plasma urea and plasma creatinine in a group of conservative, unselected patients who had both measurements made." There is therefore extra and unique information in these two measurements taken together. Not all of this information is contained in the ratio between them as the ratio alone does not indicate the magnitude of change in either of them. One alternative is to use the 'mapping' approach, in which the area of the plasma urea versus plasma creatinine diagram is divided into zones, as shown in the Figure. These zones are the prerenal zone (A), the renal zone (B)12 and the unexpectedly low urea zone (C), the measure of the magnitude of change in each zone being the plasma urea, plasma urea and creatinine, and plasma creatinine, respectively. Table 2 shows the relative frequencies of values in these three zones in several groups of patients.
In the prerenal zone (A) the plasma urea is raised proportionally more than the plasma creatinine. The most common causes of a raised urea with normal creatinine in our series of acutely iII patients plasma urea does not exclude saline depletion. What is required is a measure of the possible cause of the eventual rise in the plasma urea. These causes are increased tubular reabsorption of urea and increased production of urea, both of which can be estimated simply from simultaneous measurements of urea and creatinine in plasma and urine. a Both plasma urea and plasma creatinine measurements have been regarded as crude indices of a change in GFR because it is said that the GFR must fall to 25 % of normal before there is a significant rise in plasma concentration of either. However, our conclusions are that because of difficulties in measuring GFR (as creatinine clearance) the plasma creatinine is a more reliable detector of a fall in GFR than is the measured creatinine clearance.P
Policy
The question is in what situations should plasma electrolytes be measured, if we accept that we can no longer afford to screen as widely as we do now?
I am not certain that the case for screening well patients has been made for any of the plasma electrolytes. The situations in which the measurements of plasma potassium and sodium are essential have been discussed. If it is decided to screen for a low GFR, and there is a good case for doing so, then plasma creatinine is the measurement of choice. The plasma urea is needed in only a few situations, such as heart failure and in patients who might be bleeding into the intestine, or in patients with oliguria and dehydration (saline depletion).
Is there evidence that the number of measurements of plasma electrolytes we currently make can be reduced without hazard to patients? Our own recent experience with a restricted out-of-hours service suggests that the workload can be reduced greatly without disadvantage. When the out-of-hours work had to be restricted, the daytime emergency plasma electrolytes workload fell by the same proportion as the out-of-hours work, although no restrictions were put on it. That change suggests that requests for tests are becoming more thoughtful and discriminating.
A few months ago we had to stop measuring liver function tests on our multichannel analyser on two days a week but the arrangement was that if a clinician indicated that these tests were needed then the sample would be kept and analysed the next day. Our experience so far is that on these two days liver function tests are being requested on only 15% of inpatients, in all of whom they would previously have been measured. What is more relevant to the present discussion is that the number of requests for 279 electrolytes on inpatients fell on these days by 50 % and thus was not the result of any restrictions we had put on their measurement. These observations have to be interpreted with great care but they strongly support the view that availability creates demand.
All of these arguments, about what we should measure and whether the tests are needed, would carry little weight if the measurement of plasma electrolytes was cheap. In my view, the total cost of plasma electrolytes is very great, because plasma electrolytes have led the expansion in workload and created the need for larger and larger multichannel analysers. Nearly all the costs of these machines can therefore be attributed to the demand for plasma electrolytes, which initially was stimulated by the availability and capacity of the previous generation of machines. The costs include capital and maintenance costs, the unnecessary investigation of unrequested 'abnormal' results, job dissatisfaction, lack of resources for development, inflexibility, a 'number-crunching' factory philosophy, and inadequate resources for the investigation of problem cases.
I am well aware that this trend cannot be rapidly reversed, but it is important to appreciate the full costs of what we are doing. In larger laboratories particularly, it is essential to emphasise that the capital cost of the machines required for different (electrolyte) workloads increases in large jumps. The difference in capital cost between machines to deal with workloads of 100 or 200 samples in a day is enormous.
How have we got into this situation in which the level and nature of the activity in our laboratories is set by measurements of plasma electrolytes that no one would regard as totally necessary and which are used to assess, in my view badly, one of the most confused and complex areas of physiology, metabolic medicine, and care of acutely ill patients? I am not sure, but I believe the situation is perpetuated, and even allowed to worsen, because clinicians believe that if we in the laboratory make these measurements freely available-as we do, day and nightthen they must be useful; whereas in the laboratories we believe that if the clinicians request these measurements in large numbers-as they do, day and night-then they must be useful.
